Abstract
Target-specific monoclonal antibodies can be routinely acquired, but the sequences of naturally acquired antibodies are not always affinity-matured and methods that increase antigen affinity are desirable. Most biophysical studies have focused on the complementary determining region (CDR), which directly contacts the antigen; however, it remains difficult to increase the affinity as much as desired. While strategies to alter the CDR to increase antibody affinity are abundant, those that target non-CDR regions are scarce. Here we describe a new method, designated fluctuation editing, which identifies potential mutation sites and engineers a high-affinity antibody based on conformational fluctuations observed by NMR relaxation dispersion. Our data show that relaxation dispersion detects important fluctuating residues that are not located in the CDR and that increase antigen–antibody affinity by point mutation. The affinity-increased mutants are shown to fluctuate less in their free form and to form a more packed structure in their antigen-bound form.
Introduction
An increasing number of antibodies are now in therapeutic use1. Antibodies can be easily acquired by immunization of model animals and humanization but, because their amino acid sequences are optimized by random shuffling, the resulting affinities are not fully matured against the target molecules2. In terms of therapeutic use, there is a large demand for higher-affinity antibodies that enable the dose and cost to be minimized. It is thus important both to design antibodies with higher affinity and to elucidate the detail of antibody–antigen interactions in order to establish a basis for optimizing antibodies.
To improve our understanding of antibody–antigen interactions, many biophysical studies, including crystallographic, kinetic, and thermodynamic analyses, have characterized the events that occur at the antibody–antigen interface3–7. Based on the results of such studies, a large number of antibody mutants have been designed and tested8. Most of the studies aiming to increase the affinity of an antibody have focused on residues at the antibody–antigen interface, known as the complementary determining region (CDR)3–7. This strategy is reasonable because antibodies in nature change their specificity and affinity by randomly mutating the amino acid sequences of the CDR. In particular, the technique of molecular evolution, or phage display, has proved to be successful in affinity maturation of the CDR6. Computer-assisted structure-based affinity optimization has also been successful9. Therefore, several strategies are available to increase the affinity by modifying the CDR. However, it is difficult to increase the affinity solely by changing the CDR residues10 because a CDR sequence is relatively well optimized by nature itself, and other strategies to design antibodies with higher affinity are desirable2. One promising strategy might be to regulate the antigen-binding process of an antibody by introducing a mutation in a non-CDR region. The variable domains of the heavy chain (VH) and light chain (VL) represent potential target regions for mutation because they are sequentially and spatially connected to the CDR. At present, however, there is no established rational method that can specifically identify residues appropriate for mutation in non-CDR regions to increase the affinity to antigen.
Here, we focused on the process of dynamic binding between an antibody and its antigen in order to rationally design an antibody with higher affinity. We considered that many residues in non-CDR regions that do not directly interact with the antigen potentially contribute to the process of antibody–antigen complex formation via conformational fluctuation. Elucidating the mechanism by which these residues contribute to the binding process would provide the basis of a strategy to regulate the antibody–antigen interaction; however, the conformational fluctuations that occur in the antibody–antigen binding process are poorly understood.
A problem in attempting to regulate the conformational fluctuation of an antibody is how to choose the residues to be mutated. Without specific criteria, there are nearly 200 candidate residues in non-CDR regions that might be mutated. Here, we describe a method to identify conformational fluctuations that are relevant to the antigen-binding process. Fluctuations of an antibody can be measured by relaxation dispersion—an NMR method that quantitates conformational exchange rates on the millisecond timescale11, which applies to many biologically relevant fluctuations such as ligand-binding and folding12. We devised a scheme to select residues for mutation on the basis of relaxation dispersion data. We used the Fv fragment (the hypervariable region comprising the VH and VL domains) of an anti-lysozyme antibody, HyHEL-1013, 14, to establish the method. The Fv fragment of HyHEL-10 is easy to overexpress in Escherichia coli, and its structure, thermodynamics, and kinetics are well characterized3, 4, 13, 15.
We demonstrate that the mutation of fluctuating residues that are not located at the antigen–antibody interaction interface can lead to increased affinity of the antibody. In accordance with our method, we selected only eight candidate residues for mutation and obtained two antibodies with increased antigen affinity. To validate whether the mutations altered the fluctuations of the antibody as anticipated, we measured relaxation dispersions of the two mutants and also applied molecular dynamics simulation to quantify the fluctuations on the nanosecond timescale. Our findings indicate that the mutants have a tight packing structure in the bound form, accounting for their increased antigen affinity.
Results
Strategy to identify potential mutation sites based on conformational fluctuation
To increase the affinity of an antibody by editing its conformational fluctuations, we devised the following scheme to introduce a mutation at a specific fluctuating residue as shown in Fig. 1 Selection: Conformational fluctuations of an antibody in the free and bound forms are measured by relaxation dispersion. Fluctuation editing: Residues for which a mutation may possibly change the fluctuation are chosen according to the following four criteria: displays relaxation dispersion; located at a non-CDR region; large size (i.e., residues other than Ala, Gly, Ser, Thr, or Val); accessible surface area (ASA) larger than 20%. These criteria are based on the assumptions that mutation of a large fluctuating residue to a smaller residue (Ala) will effectively change the local fluctuation around it, and that residues with a small ASA, or a large buried surface area, will be important for folding of the antibody and should be avoided. Evaluation: Affinity, stability, and fluctuations of the mutants are examined to judge whether the mutants are better than the wild type as anticipated. Validation: To verify the changes in conformation fluctuation of the mutants, relaxation dispersion and MD simulation are conducted.
Selection: Analysis of fluctuations of HyHEL-10 in the free and lysozyme-bound forms
First, we measured the1H-15N heteronuclear single quantum coherence (HSQC) spectra of the free and lysozyme-bound forms of HyHEL-10 (Fig. 2a). Chemical shift differences between the two spectra were mainly observed in the VH domain, especially at the contact surface of the VH and VL domains, and in the outer loop of the VH domain (Fig. 2b,c). This is consistent with the structural differences between the free and lysozyme-bound HyHEL-10 structures (Fig. 2d). The relative orientation of the VH and VL domains differs between the free and bound crystal structures. Each individual domain in the free and bound structures is superimposable with a root-mean-square deviation (RMSD) of 0.32 Å for the VH domain and 0.25 Å for the VL domain. By contrast, the other domain not used for superimposition differs substantially. Both the crystal structures and NMR spectra indicate that the VH domain undergoes a more obvious structural change upon binding to lysozyme.
Next, we conducted R 2 relaxation dispersion experiments for free HyHEL-10, and observed relaxation dispersions in a wide area of the VH and VL domains (Fig. 3a–c). The fluctuating residues could be divided into two groups (Fig. 3d): one fluctuating at a k ex rate of 840 ± 15 s−1, and one fluctuating at 2033 ± 50 s−1. This result indicates that these regions transiently interconvert with different conformations in solution. Note that the VH and VL domains maintained a tight complex (Fv fragment) during the R 2 dispersion measurements because neither of the domains can exist alone. However, it is possible that local inter-domain interactions were transiently broken and reformed, and this type of process may have contributed to R 2 dispersions. Because the VH and VL domains exist only as a complex, such processes can be treated as internal motions of a single molecule. In Fig. 3c, the amplitude of the relaxation dispersion curve, R ex, which indicates an excess contribution to the transverse relaxation rate R 2 caused by conformational exchange, is mapped on the crystal structure of free HyHEL-10. Interestingly, most of the relaxation dispersions observed for free HyHEL-10 disappeared when HyHEL-10 formed a complex with lysozyme as typically shown for H:R71 in Fig. 3a. This result suggests that binding to lysozyme stabilizes HyHEL-10. Because all of the R ex values were very small, we were unable to determine the conformational exchange parameters precisely. Nevertheless, the smaller R ex values in the bound form imply that mutation of the fluctuating residues of free HyHEL-10 might change the fluctuation favorably for lysozyme binding.
Fluctuation editing: Introducing mutation
Among 32 fluctuating residues identified in free HyHEL-10, small residues and residues buried in the hydrophobic interior with ASA values smaller than 20% were excluded from mutation according to the scheme shown in Fig. 1. The remaining eight residues possessed large side chains and were exposed to the solvent (Supplementary Fig. 1). Each of the eight residues was mutated to alanine, with the expectation that the mutation would change fluctuations around this residue, leading to increase the affinity (Supplementary Table 1).
Evaluation: Affinity and stability of the mutants
We attempted to express recombinant proteins of all eight antibody mutants, and obtained four mutants in sufficient quantity for subsequent analyses: H:Q3A, H:R44A, H:R71A, and L:R45A (Supplementary Fig. 1), where H and L correspond to the VH and VL domains, respectively. Other mutants could not be obtained due to improper folding during the refolding step. First, the affinity of the mutants for lysozyme was measured by isothermal titration calorimetry (ITC). The H:R44A mutant aggregated during the ITC experiment, and thus was not further analyzed. The association constant K A of the H:Q3A mutant ((2.2 ± 0.25) × 108 M) was little changed from that of the wild type14 (WT; 1.8 × 108 M). However, this mutant was not stable enough for further fluctuation analysis. In addition to the eight mutants, we also conducted a control ITC measurement for L:H34A, which has a mutation at one of the excluded residues (L:H34). As a result, its affinity was little changed from that of WT ((2.8 ± 0.51) × 108 M), which supports the concept of fluctuation editing.
By contrast, the H:R71A and L:R45A mutants had K A values that were more than 10 times higher than that of WT ((2.0 ± 0.88) × 109 M and (2.0 ± 0.46) × 109 M, respectively) (Supplementary Fig. 2). For H:R71A, a higher enthalpy change (ΔH = −99.50 ± 0.25 kJ/mol), compensating the loss of entropy (TΔS = −47.33 ± 1.07 kJ/mol), was the driving force of the increased affinity: ΔH = −78.2 kJ/mol and TΔS = −32.2 kJ/mol in the case of WT. The higher enthalpy change suggests the formation of new interactions in the mutant. For L:R45A, a decrease in the loss of entropy (TΔS = −16.71 ± 0.56 kJ/mol), compensating the loss of enthalpy (ΔH = −68.88 ± 0.21 kJ/mol), contributed to the increased affinity. Further ITC analyses measured at different temperatures showed that the heat capacity change ΔC p for binding was −2.85 ± 0.08 and −1.04 ± 0.03 kJ/mol/K for H:R71A and L:R45A, respectively (Table 1). For WT, the ΔC p for lysozyme binding was −1.4 kJ/mol/K13. Because a negative ΔC p value represents dehydration from hydrophobic residues upon binding16, these results show that the dehydration occurring upon binding is larger for H:R71A than for WT. This result suggests that the fluctuation of H:R71A in the free form is suppressed but the H:R71A undergoes structural rearrangement after binding by the induced-fit mechanism. The ΔC p of L:R45A was similar to that of WT.
Table 1.
T [K] | ΔH [kJ/mol] | ΔC p [kJ/mol/K] | |
---|---|---|---|
H:R45A | 293 | 68.88 ± 0.21 | −1.04 ± 0.03a |
298 | −73.50 ± 0.15 | ||
303 | −79.38 ± 0.23 | ||
L:R71A | 293 | −99.50 ± 0.25 | −2.85 ± 0.07a |
298 | −113.40 ± 0.36 | ||
303 | −130.29 ± 1.45 | ||
WT | 293 | −1.4b |
aDerived from ΔH values measured at 293, 298, and 303 K. bTaken from ref. 14.
Next, we analyzed the thermal stability of H:R71A and L:R45A by differential scanning calorimetry (DSC) to gain insight into the mechanism by which the mutations increased the affinity. The ΔH value of the lysozyme-bound form of H:R71A and L:R45A was 302 and 313 kcal/mol, respectively (Supplementary Table 2, Supplementary Fig. 4). These values are larger than that of WT (247 kcal/mol), indicating that both mutants form more stable complexes as compared with WT. For H:R71A, the large change in ΔC p and the large contribution of ΔH to binding suggest that formation of the stable complex is accomplished by tighter packing of the outer loop and CDR-H3, which are adjacent to H:Ala71. On the other hand, for L:R45A, where the mutated residue is involved in the VL loop adjacent to the VH domain (Supplementary Fig. 1), the small change in ΔC p and the small contribution of ΔS shows that the structural rearrangement that occurs upon interaction with the antigen is decreased by the mutation. This is thought to be caused by a slight reorientation of the VH and VL domains of the free form to a more favorable binding orientation.
Validation 1: Fluctuation of the affinity-increased mutants in the free form
The HSQC spectra of H:R71A and L:R45A in their free form were similar to that of free WT, indicating that the overall structures of the mutants are similar to that of WT (Supplementary Fig. 3). For H:R71A, however, several residues adjacent to the mutated residue in the outer loop showed relatively large changes in chemical shift (Fig. 4a), suggesting that the conformational change induced by the Ala mutation is confined to the local area near the VH domain. For L:R45A, chemical shift changes were observed in both the VL and VH domains (Fig. 4b), which supports the ITC data implying that the Ala mutation in L:R45A causes a reorientation of VH and VL, leading to more favorable lysozyme binding.
To examine whether the mutations that we introduced altered the conformational fluctuations of HyHEL-10 as intended, we measured the R 2 relaxation dispersions for each mutant (Fig. 4c,d). The exchange rate, k ex, for H:R71A and L:R45A was 753 ± 23 and 657 ± 15 s−1, respectively. These rates were slightly slower than that observed for the corresponding region in WT. For H:R71A, the relaxation dispersion profiles of several residues, including the mutated residue Ala71 and those in the outer loop and CDR-H3 (Gln3, Val24, Thr25, Ser28, Ser31, Trp36, Thr56, Ser68, and Asp72) became flat lines, meaning that no fluctuations of these residues were observed; however, relaxation dispersions in the VL domain, which is distal to H:Ala71, were little influenced by the mutation (Fig. 4e). Together with the chemical shift changes observed for H:R71A, these results suggest that the H:R71A mutation changed the local conformation and fluctuations of the region adjacent to H:Ala71 in the VH domain.
For L:R45A, no relaxation dispersions of residues at the interface of the VL and VH domains were observed (Fig. 4f), including His33, Gly84, Phe87, and Phe98 in the VL domain, and Glu46 in the VH domain. In addition, similar to H:R71A, relaxation dispersions of residues in the outer loop and CDR-H3 were not observed (Val24, Thr25, Ser28, Ser31, Trp36, and Asp72 in the VH domain), suggesting that these residues are involved in the same fluctuation network that spreads over the both VH and VL domains. In particular, H:Glu46 is possibly an important residue for forming the fluctuation network. Indeed, the H:E46A mutant was not expressed in Escherichia coli, suggesting the importance of H:Glu46 in domain packing. The results indicate that suppressing fluctuations in the VH domain is important for increasing the affinity of HyHEL-10.
Validation 2: Comparison of fast timescale motion in the bound form
For bound WT HyHEL-10, relaxation dispersion provided little information about fluctuations on the millisecond timescale. Because fluctuations that are faster than the millisecond timescale cannot be detected by R 2 relaxation dispersion, we analyzed and visualized fluctuations of the bound form on a faster timescale by using molecular dynamics (MD) simulation. We conducted a 130-ns MD simulation for the lysozyme-bound form of WT, H:R71A, and L:R45A. The overall structure did not change markedly during the simulation: the RMSD of the simulated structures from the average structure, which were aligned by Cα atoms, was less than 1.5, 1.2, and 1.4 Å for WT, H:R71A, and L:R45A, respectively. However, a local structural change was observed near the area of the mutated residue in both mutants.
We measured the intra-atomic distances to examine the effect of the mutation. For H:R71A, the outer loop was a median value of 0.38 Å closer to CDR-H3 as compared with WT (Fig. 5a,b). For L:R45A, the adjacent VH loop and VL loop were a median value of 1.1 Å closer as compared with WT (Fig. 5c,d). These results indicate that the bound form of both mutants adopts a more packed conformation. The MD results suggest the possibility that the fluctuating H:Arg71 residue in WT disrupts the packing of the outer loop and CDR-H3 in the bound form (Fig. 5a) while the side chain of L:Arg45 flips between the VH and VL domains to disrupt their packing. For L:R45A, the VH and VL domains are more packed in the bound form (Fig. 5c,d). These data support the results of the ITC and DSC experiments showing an increase in the stability of the antigen-bound form of HyHEL-10.
Discussion
We have described a method to increase the affinity of an antibody by regulating or “editing” its conformational fluctuation. We have set criteria to select specific residues in non-CDR regions that are distant from the antigen–antibody interface as candidates for mutation among the fluctuating residues detected by relaxation dispersion. Via this approach, we have succeeded in increasing the affinity of HyHEL-10 for lysozyme by more than 10-fold through a single Ala point mutation of a fluctuating residue. This increase in affinity is comparable to that achieved by molecular evolution methods targeting CDR residues, where the affinity may be increased by 10–20-fold in a single cycle8. To our best knowledge, this is the first study to show that the affinity of an antibody can be increased by rationally targeting the fluctuations of non-CDR regions.
NMR is one of the most powerful tools to analyze conformational fluctuations quantitatively, especially because it provides site-specific information. Although several prominent studies of antibodies using NMR, including those of conformational dynamics, have been reported17–21, studies on microsecond to millisecond fluctuations of the peptide backbone of antibodies have been scarce. Our study has shown that relaxation dispersion is suitable for detecting and quantifying fluctuations in free HyHEL-10 on the millisecond timescale. Although fluctuations of lysozyme-bound HyHEL-10 are barely observed by relaxation dispersion, MD simulation can be utilized for analyzing the motions of the bound form on the nanosecond timescale.
How do mutations of residues fluctuating far from the antibody–antigen interface increase the affinity? The relaxation dispersion experiments showed that fluctuations in the VH domain are suppressed in the mutants; such conformational suppression will be important for packing of the antibody upon antibody–antigen interaction, resulting in an increase in affinity. A previous crystallographic study suggested that the VH domain in WT is flexible, enabling structural adjustment upon binding3. Our mutation studies suggest that this flexibility in the outer loop may be an unfavorable factor in antigen binding. Together with the MD data, we show that motions unfavorable for binding occur in the VH domain of WT. Removing the unfavorable fluctuations by a point Ala mutation leads to a rearrangement of intra-molecular interactions. The relaxation dispersion data also suggest that the fluctuation suppressed at the mutated residue is transmitted to distal regions, including the antibody–antigen interface22.
In summary, we have described a method of “fluctuation editing” to specifically detect and engineer intramolecular fluctuations. Although previous studies have reported the functional modification of proteins through changes in fluctuation23–25, our study is the first to propose a systematic experimental method to detect and engineer conformational fluctuations that are important for distal regulation. Via our method, we showed that mutation of a large residue to Ala decreases the number of the fluctuating residues in the antibody and that Ala mutation of large fluctuating residues is effective for increasing antibody–antigen affinity. Mutations of other residues selected on the basis of alternative criteria might further increase antigen affinity by a different mechanism. Furthermore, it would be worth combining our method with other protein-engineering methods, such as phage display or computer-assisted rational design26. Typical studies using phage display have focused on residues at the antibody–antigen interface2–6, 10, 13, 14. To apply phage display to non-CDR regions, however, it is necessary to set a criterion to specify a target area for molecular evolution, because of the high number of candidate residues in non-CDR regions. In this regard, an advantage of our fluctuation editing method is that it can narrow down the candidate residues in non-CDR regions that are potentially important for antigen binding.
Recent developments in NMR and isotope-labeling methods have enabled us to study the structure and dynamics of very large proteins with masses as large as 1 MDa27. For IgG, Arbogast et al. recently reported that Fc and Fab fragments are amenable to NMR measurements, at least for IgG1κ. Therefore, it is highly likely that our method can be applied directly to Fc and Fab19.
Methods
Protein expression and purification
The cDNA of HyHEL-1014 was cloned into a pET22a vector. [15N]- and [13C,15N]-HyHEL-10 proteins were expressed as inclusion bodies in BL21 (DE3) cells grown in M9 minimal medium. When the OD600 of the cell culture reached 1.2–1.5 at 37 °C, isopropylthio-b-D-galactoside (IPTG) was added to the medium at a concentration of 1 mM to induce protein expression. The protein-containing cells were lysed and centrifuged. The pellet was washed three times in 50 mM Tris-HCl buffer with sonication. The HyHEL-10 Fv fragment was dissolved in 6 M guanidine hydrochloride (Gdn-HCl) buffer and prepared at a concentration of 5–6 mg/ml and dialyzed against refolding buffer (100 mM Tris-HCl, 0.5 mM GSSG, and 5 mM GSH)14 over night. The dissolved protein was purified using lysozyme-immobilized affinity column as described previously13. After affinity chromatography, the obtained HyHEL-10 was further purified with size exclusion chromatography under the condition of 150 mM phosphate buffer with 300 mM NaCl. The final yield of the protein was 10 mg/l of Escherichia coli culture.
NMR methods
Three-dimensional spectra of HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB, HN(CO)CACB, and15N NOESY-HSQC were measured on an AVANCE DRX600 spectrometer (Bruker BioSpin) for sequential assignments of the backbone1H,13C, and15N chemical shifts28 of free and bound HyHEL-10 using protein dissolved at 0.8–0.9 mM in NMR buffer (95% H2O/5% D2O, 20 mM PBS [pH 7.4], 143 mM NaCl). NMR data were processed and analyzed as previously described29.
15N effective R 2 relaxation rates were measured at 37 °C on AVANCE DRX600 and AVANCE DMX750 spectrometers (Bruker BioSpin) using the1H continuous-wave decoupled Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence30. Effective R 2 rates were calculated as described previously11. For L:R45A, non-uniform sampling and the SIFT method31, were used to shorten the experimental time because the free form of this mutant was not stable enough to measure a full set of R 2 relaxation spectra in the standard way. Relaxation dispersion data whose R 2 values changed by < 1 s−1 over the entire range of τcp were excluded.
The relaxation dispersion curves were fitted globally by using the program GLOVE12 with a certain cluster in which neighboring residues were assumed to fluctuate at the same exchange rate. The Carver and Richards equation and the Luz and Meiboom equation were used to fit the relaxation dispersions. The Carver and Richards equation is appropriate for a two-state exchange model (major ↔ minor) in the intermediate or slow exchange regime, and a curve fit to this equation yields the population-average intrinsic transverse relaxation rate (R 2 0), the exchange rate k ex, the chemical shift difference between states (Δω), and the populations of the major and minor states (p major, p minor). The Luz and Meiboom equation is valid only for the fast exchange regime, and a curve fit to this equation yields R 2 0, k ex, and p major p minorΔω2. Using these two equations, we tested several global fits for various clusters involving different groups of residues. The fitting quality was compared among different fits by the reduced χ2 value (χ2 divided by the degree of freedom) and F test to determine the appropriate exchange regime and clusters to describe the fluctuations observed by relaxation dispersion. The Luz and Meiboom equation fitted better for H:R71A and L:R45A, whereas the Carver and Richards equation was suitable for fitting free WT data.
Isothermal titration calorimetry measurements
Protein samples were dialyzed against PBS (20 mM PBS [pH 7.4], 143 mM NaCl), and the concentrations of the antibody and lysozyme were adjusted to approximately 30 μM and 2 μM, respectively. Thermodynamic analysis was performed to investigate the interaction between lysozyme and antibody using an VP-ITC isothermal titration calorimeter (MicroCal). The antibody was titrated against lysozyme 25 times with the amount of 10 μl and the duration of 20 seconds for each titration. ITC experiments were carried out at 20, 25, and 30 °C under otherwise identical conditions. The experimental data were baseline-corrected and subjected to K A calculation by using the software package ORIGIN for ITC(MicroCal) as described previously14.
Differential scanning calorimetry measurements
Protein samples were dialyzed against PBS (20 mM PBS [pH 7.4], 143 mM NaCl), and the concentrations were adjusted to approximately 2 mg/ml. To examine the heat stability of the proteins, heat capacity curves were obtained by an ultrasensitive VP-DSC scanning microcalorimeter (MicroCal) at a heating rate of 1 K/min with a sample cell volume of 0.5 ml. The obtained data were baseline-corrected and subjected to deconvolution by using the software package ORIGIN for DSC (MicroCal) as described previously32.
Molecular dynamics simulation
Three-dimensional coordinates of WT HyHEL-10 were obtained from the PDB database (PDB ID: 1C08)3. Models of the H:R71A and L:R45A mutants were constructed using the “mutagenesis” function implemented in PyMOL33. Water molecules that were resolved in the crystal structure were included in the simulations. Preparation of initial structures for the MD simulation, energy minimization, and heating was performed as described previously34. The minimization and equilibration runs were conducted by using GROMACS version 5.0.435. Each production run was carried out for 130 ns, maintaining the temperature at 300 K and the pressure at 1.0 × 105 Pa. Distances between the two atoms were measured for the structures extracted every nanosecond from the 130-ns simulation trajectory using the program CPPTRAJ36. The ASA of the VH and VL domains was calculated by using PyMOL33.
Electronic supplementary material
Acknowledgements
We thank Dr. Koichi Kato (Institute for Molecular Science and Okazaki Institute for Integrative Biosciences) for useful discussion. This project was supported by the Japanese Society for the Promotion of Science, research grant number 13J09564 and JP17H05893, and the Nanotechnology Platform Program (Molecule and Material Synthesis) of MEXT. There is no conflict of interest among the authors. We thank Ms. Yukiko Isono for the help in preparation of the protein sample for ITC measurements.
Author Contributions
S.Y., K.T., and K.S. designed the overall research and the experiments, and analyzed the data. Y.M. designed the MD simulation experiments. S.Y. and K.S. wrote the manuscript.
Competing Interests
The authors declare that they have no competing interests.
Footnotes
Electronic supplementary material
Supplementary information accompanies this paper at doi:10.1038/s41598-017-10246-9
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Brit. J. Pharmacol. 2009;157:220–233. doi: 10.1111/j.1476-5381.2009.00190.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA. 1995;92:1254–1256. doi: 10.1073/pnas.92.5.1254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kondo H, Shiroishi M, Matsushima M, Tsumoto K, Kumagai I. Crystal structure of anti-Hen egg white lysozyme antibody (HyHEL-10) Fv-antigen complex. Local structural changes in the protein antigen and water-mediated interactions of Fv-antigen and light chain-heavy chain interfaces. J. Biol. Chem. 1999;274:27623–27631. doi: 10.1074/jbc.274.39.27623. [DOI] [PubMed] [Google Scholar]
- 4.Shiroishi M, et al. Structural consequences of mutations in interfacial Tyr residues of a protein antigen-antibody complex. The case of HyHEL-10-HEL. J. Biol. Chem. 2007;282:6783–6791. doi: 10.1074/jbc.M605197200. [DOI] [PubMed] [Google Scholar]
- 5.Diskin R, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 2011;334:1289–1293. doi: 10.1126/science.1213782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature. 1991;352:624–628. doi: 10.1038/352624a0. [DOI] [PubMed] [Google Scholar]
- 7.Braden BC, Goldman ER, Mariuzza RA, Poljak RJ. Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3. Immunol. Rev. 1998;163:45–57. doi: 10.1111/j.1600-065X.1998.tb01187.x. [DOI] [PubMed] [Google Scholar]
- 8.Maynard J, Georgiou G. Antibody engineering. Annu. Rev. Biomed. Eng. 2000;2:339–376. doi: 10.1146/annurev.bioeng.2.1.339. [DOI] [PubMed] [Google Scholar]
- 9.Clark LA, et al. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci. 2006;15:949–960. doi: 10.1110/ps.052030506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Schier R, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 1996;263:551–567. doi: 10.1006/jmbi.1996.0598. [DOI] [PubMed] [Google Scholar]
- 11.Sugase K, Dyson HJ, Wright PE. Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature. 2007;447:1021–1025. doi: 10.1038/nature05858. [DOI] [PubMed] [Google Scholar]
- 12.Sugase K, Konuma T, Lansing JC, Wright PE. Fast and accurate fitting of relaxation dispersion data using the flexible software package GLOVE. J. Biomol. NMR. 2013;56:275–283. doi: 10.1007/s10858-013-9747-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Tsumoto K, et al. Role of Tyr residues in the contact region of anti-lysozyme monoclonal antibody HyHEL10 for antigen binding. J. Biol. Chem. 1995;270:18551–18557. doi: 10.1074/jbc.270.31.18551. [DOI] [PubMed] [Google Scholar]
- 14.Tsumoto K, et al. Contribution to antibody-antigen interaction of structurally perturbed antigenic residues upon antibody binding. J. Biol. Chem. 1994;269:28777–28782. [PubMed] [Google Scholar]
- 15.Pons J, Rajpal A, Kirsch JF. Energetic analysis of an antigen/antibody interface: alanine scanning mutagenesis and double mutant cycles on the HyHEL-10/lysozyme interaction. Protein sci. 1999;8:958–968. doi: 10.1110/ps.8.5.958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Prabhu NV, Sharp KA. Heat capacity in proteins. Annu. Rev. Phys. Chem. 2005;56:521–548. doi: 10.1146/annurev.physchem.56.092503.141202. [DOI] [PubMed] [Google Scholar]
- 17.Yagi, H. et al. Backbone H, C, and N resonance assignments of the Fc fragment of human immunoglobulin G glycoprotein. Biomol. NMR Assig. (2014). [DOI] [PMC free article] [PubMed]
- 18.Williams DC, Jr., Rule GS, Poljak RJ, Benjamin DC. Reduction in the amide hydrogen exchange rates of an anti-lysozyme Fv fragment due to formation of the Fv-lysozyme complex. J. Mol. Biol. 1997;270:751–762. doi: 10.1006/jmbi.1997.1122. [DOI] [PubMed] [Google Scholar]
- 19.Arbogast LW, Brinson RG, Marino JP. Mapping monoclonal antibody structure by 2D 13C NMR at natural abundance. Anal. Chem. 2015;87:3556–3561. doi: 10.1021/ac504804m. [DOI] [PubMed] [Google Scholar]
- 20.Tugarinov V, et al. NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. Structure. 2000;8:385–395. doi: 10.1016/S0969-2126(00)00119-2. [DOI] [PubMed] [Google Scholar]
- 21.Arata Y, Kato K, Takahashi H, Shimada I. Nuclear magnetic resonance study of antibodies: a multinuclear approach. Methods Enzymology. 1994;239:440–464. doi: 10.1016/S0076-6879(94)39017-7. [DOI] [PubMed] [Google Scholar]
- 22.Gasper PM, Fuglestad B, Komives EA, Markwick PR, McCammon JA. Allosteric networks in thrombin distinguish procoagulant vs. anticoagulant activities. Proc. Natl. Acad. Sci. USA. 2012;109:21216–21222. doi: 10.1073/pnas.1218414109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.van den Bedem H, Bhabha G, Yang K, Wright PE, Fraser JS. Automated identification of functional dynamic contact networks from X-ray crystallography. Nat. Methods. 2013;10:896–902. doi: 10.1038/nmeth.2592. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Feher VA, Durrant JD, Van Wart AT, Amaro RE. Computational approaches to mapping allosteric pathways. Curr. Opin. Struct. Biol. 2014;25:98–103. doi: 10.1016/j.sbi.2014.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Harada E, Sugishima M, Harada J, Fukuyama K, Sugase K. Distal regulation of heme binding of heme oxygenase-1 mediated by conformational fluctuations. Biochemistry. 2015;54:340–348. doi: 10.1021/bi5009694. [DOI] [PubMed] [Google Scholar]
- 26.Fleishman SJ, et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science. 2011;332:816–821. doi: 10.1126/science.1202617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Rosenzweig R, Kay LE. Bringing dynamic molecular machines into focus by methyl-TROSY NMR. Annu. Rev. Biochem. 2014;83:291–315. doi: 10.1146/annurev-biochem-060713-035829. [DOI] [PubMed] [Google Scholar]
- 28.Ikura M, Kay LE, Bax A. A novel approach for sequential assignment of 1H, 13C, and 15N spectra of proteins: heteronuclear triple-resonance three-dimensional NMR spectroscopy. Application to calmodulin. Biochemistry. 1990;29:4659–4667. doi: 10.1021/bi00471a022. [DOI] [PubMed] [Google Scholar]
- 29.Yanaka S, et al. Peptide-dependent conformational fluctuation determines the stability of the human leukocyte antigen class I complex. J. Biol. Chem. 2014;289:24680–24690. doi: 10.1074/jbc.M114.566174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Hansen DF, Vallurupalli P, Kay LE. An improved 15N relaxation dispersion experiment for the measurement of millisecond time-scale dynamics in proteins. J. Phys. Chem. B. 2008;112:5898–5904. doi: 10.1021/jp074793o. [DOI] [PubMed] [Google Scholar]
- 31.Matsuki Y, Konuma T, Fujiwara T, Sugase K. Boosting protein dynamics studies using quantitative nonuniform sampling NMR spectroscopy. J. Phys. Chem. B. 2011;115:13740–13745. doi: 10.1021/jp2081116. [DOI] [PubMed] [Google Scholar]
- 32.Motozono C, Yanaka S, Tsumoto K, Takiguchi M, Ueno T. Impact of intrinsic cooperative thermodynamics of peptide-MHC complexes on antiviral activity of HIV-specific CTL. J. Immunol. 2009;182:5528–5536. doi: 10.4049/jimmunol.0803471. [DOI] [PubMed] [Google Scholar]
- 33.The PyMol Molecular Graphics System, V., Schrodinger, LLC. The PyMol Molecular Graphics System, Version 1.5.0.3, Schrodinger, LLC. (2010).
- 34.Moriwaki Y, et al. Heme binding mechanism of structurally similar iron-regulated surface determinant near transporter domains of Staphylococcus aureus exhibiting different affinities for heme. Biochemistry. 2013;52:8866–8877. doi: 10.1021/bi4008325. [DOI] [PubMed] [Google Scholar]
- 35.Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 2008;4:435–447. doi: 10.1021/ct700301q. [DOI] [PubMed] [Google Scholar]
- 36.Roe DR, Cheatham TE. PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 2013;9:3084–3095. doi: 10.1021/ct400341p. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.